JW Lifescience Corporation

KSE 234080.KS

JW Lifescience Corporation Gross Profit Margin for the year ending December 31, 2023: 25.31%

JW Lifescience Corporation Gross Profit Margin is 25.31% for the year ending December 31, 2023, a -0.63% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

JW Lifescience Corporation Gross Profit Margin for the year ending December 31, 2022 was 25.47%, a -12.01% change year over year.
JW Lifescience Corporation Gross Profit Margin for the year ending December 31, 2021 was 28.95%, a -10.71% change year over year.
JW Lifescience Corporation Gross Profit Margin for the year ending December 31, 2020 was 32.42%, a 13.54% change year over year.
JW Lifescience Corporation Gross Profit Margin for the year ending December 31, 2019 was 28.55%, a 12.17% change year over year.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

KSE: 234080.KS

JW Lifescience Corporation

CEO	Sungnam Cha
IPO Date	Oct. 27, 2016
Location	South Korea
Headquarters	28, Hanjin 1-gil
Employees	301
Sector	Health Care
Industries Pharmaceuticals Biotechnology Water

Description

JW Lifescience Corporation engages in the development, production, and sale of infusion solutions in South Korea and internationally. It offers basic intravenous fluid that comprises water, electrolytes, and glucose; nutrient infusion solution that consist of nutrients, such as amino acids, lipids, proteins, vitamins, and minerals; and special infusion solutions. The company was formerly known as JW Co. Ltd. and changed its name to JW Lifescience Corporation in April 2011. JW Lifescience Corporation was founded in 1994 and is based in Dangjin, South Korea.

Key trends

Past 5 years